Day: June 5, 2023

Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases

Trial to Evaluate Proprietary Human anti-suPAR Monoclonal Antibody for Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers Expects to Complete Enrollment...

Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023

SAN CARLOS, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which...

error: Content is protected !!